Emergency Department, 305 Hospital of People's Liberation Army, Beijing 100017, China.
College of Pharmaceutical and Biology Engineering, Shenyang University of Chemical Technology, Shenyang 110142, China.
Molecules. 2022 Jul 2;27(13):4275. doi: 10.3390/molecules27134275.
Non-canonical nuclear factor kappa B (NF-κB) signaling pathway regulates many physiological and pathological processes, including liver homeostasis and diseases. Recent studies demonstrate that non-canonical NF-κB signaling pathway plays an essential role in hyperglycemia, non-alcoholic fatty liver disease, alcoholic liver disease, liver regeneration, liver injury, autoimmune liver disease, viral hepatitis, and hepatocellular carcinoma. Small-molecule inhibitors targeting to non-canonical NF-κB signaling pathway have been developed and shown promising results in the treatment of liver injuries. Here, the recent advances and future prospects in understanding the roles of the non-canonical NF-κB signaling pathways in the regulation of liver diseases are discussed.
非经典核因子 kappa B（NF-κB）信号通路调节许多生理和病理过程，包括肝脏稳态和疾病。最近的研究表明，非经典 NF-κB 信号通路在高血糖、非酒精性脂肪性肝病、酒精性肝病、肝再生、肝损伤、自身免疫性肝病、病毒性肝炎和肝细胞癌中发挥着重要作用。针对非经典 NF-κB 信号通路的小分子抑制剂已经被开发出来，并在肝脏损伤的治疗中显示出有前景的结果。在这里，讨论了近年来在理解非经典 NF-κB 信号通路在调节肝脏疾病中的作用方面的进展和未来前景。
